Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

REGENXBIO Announces Dosing of First Patient in Trial for Wet AMD Using Suprachoroidal Delivery

americanpharmaceuticalreviewSeptember 14, 2020

Tag: Regenxbio , RGX-314 , wet AMD

PharmaSources Customer Service